11th Nov 2024 12:07
(Alliance News) - Angle PLC on Monday said its in-vitro diagnostic Parsortix system was successfully used in a non-small cell lung cancer study to help identify patients becoming resistant to treatment.
The Guildford, England-based liquid biopsy company said the study undertaken by the National & Kapodistrian University of Athens used the Parsortix system to isolate and harvest circulating tumour cells from 30 patients with epidermal growth factor receptor-mutated non-small cell lung cancer, who were undergoing treatment with osimertinib.
Osimertinib, developed by AstraZeneca PLC under the brand name Tagrisso, is an epidermal growth factor receptor inhibitor.
The dual analysis technique that looked at both circulating tumour cells DNA and circulating tumour DNA identified an increased number of patients with the epidermal growth factor receptor T790M resistance mutation and DNA methylation, compared to individual analysis.
As a result, the technique could enable the identification of patients becoming resistant to treatment before the disease progresses too much.
Further analysis of circulating tumour cells also identified druggable molecular markers that provided information on the potential benefits of combined targeted treatment, as well as possible therapies for patients who have become resistant to treatment with osimertinib.
Chief Scientific Officer Karen Miller said: "This study supports our pharma services business by demonstrating how dual molecular analysis of Parsortix-enriched [circulating tumour cells] and [circulating tumour DNA] could improve patient stratification in clinical trials investigating new targeted therapies or new therapy combinations. This approach could ultimately lead to the development of more targeted drugs or better drug combinations that could result in better outcomes for patients, all of which may require a Parsortix-based companion diagnostic to support regulatory approval."
Shares in Angle were up 31% at 10.85 pence each in London on Monday morning.
By Emily Parsons, Alliance News reporter
Comments and questions to [email protected]
Copyright 2024 Alliance News Ltd. All Rights Reserved.